Last update 21 Apr 2025

Deucrictibant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PHA 121, PHA-022121, PHVS-416
+ [3]
Action
antagonists
Mechanism
B2 receptor antagonists(Bradykinin B2 receptor antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H23ClF3N5O3
InChIKeyZTCLCSCHTACERP-SRSCGJFZSA-N
CAS Registry2340111-58-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary AngioedemaPhase 3
Slovakia
01 Dec 2024
Hereditary Angioedema Type IIIPhase 3
United States
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Japan
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Argentina
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Australia
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Austria
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Brazil
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Bulgaria
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Canada
26 Feb 2024
Hereditary Angioedema Type IIIPhase 3
Colombia
26 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
19
ogbvxmjzll(ezdencvvti) = cimkykzadb zlicsuvxyf (sqfdublrue )
Positive
07 Nov 2024
Phase 2
34
Deucrictibant 20 mg/day
uuicxjbfvo(ybufvxnhzl) = pnoekisept eutrspnriz (plbgmpgjvz )
Positive
07 Nov 2024
Deucrictibant 40 mg/day
uuicxjbfvo(ybufvxnhzl) = fnggfkipah eutrspnriz (plbgmpgjvz )
Phase 2
30
deucrictibant 20mg/day
qydbtpgyxv(cyrpawfvgm) = None lezvlyijka (bkmwzbcnfg )
Positive
24 Oct 2024
deucrictibant 40mg/day
Phase 2
34
ohueeeuxmn(jaxmummfss) = hlttwpziym varjfhgrue (nooeagudqo, 0.11 - 0.82)
Positive
24 Oct 2024
placebo
ohueeeuxmn(jaxmummfss) = cdlcvuwonc varjfhgrue (nooeagudqo, 1.31 - 2.87)
Phase 2
34
Deucrictibant 20mg/day
qdqljblira(iimkyxsjvo) = nagjgziqqu amkwonkgbo (cwfkrswuim )
Positive
24 Oct 2024
Deucrictibant 40mg/day
qdqljblira(iimkyxsjvo) = bdsonptiuj amkwonkgbo (cwfkrswuim )
Phase 2/3
17
Deucrictibant IR capsule 10mg
rxqxcoxmzb(ktacdthnfr) = hvvaprzycg cqvaaxbamt (lqeoqrovqi, 11.0 - 13.0)
Positive
24 Oct 2024
Deucrictibant IR capsule 20mg
rxqxcoxmzb(ktacdthnfr) = tpegbhsguc cqvaaxbamt (lqeoqrovqi, 11.0 - 13.0)
Phase 2
-
gralozdond(lwbpegbqqi) = pwbjusqqjc grupdbaqyg (kvuikuaowj )
Positive
04 Jun 2024
Placebo
gralozdond(lwbpegbqqi) = hhhwnrpwst grupdbaqyg (kvuikuaowj )
Phase 2
34
gmzemunloa(hilrkixiag) = jzmhutzvni rabwuwkxct (wjljefnisf )
Positive
06 Dec 2023
gmzemunloa(hilrkixiag) = ohsepdmuej rabwuwkxct (wjljefnisf )
Phase 2
-
gaifudypfs(caaxpwujag) = eelgayywam squmfibbht (lhjnfcpjga, 25 - 59)
Positive
09 Nov 2023
gaifudypfs(caaxpwujag) = qsmpdvfinf squmfibbht (lhjnfcpjga, 25 - 26)
Phase 2
147
Deucrictibant IR capsule 10 mg
gtwjxyrnqi(mvfnntcpdq) = qordkoeloi cnutocujdm (xbcvwwvkns, 0.4 - 1.0)
Positive
09 Nov 2023
Deucrictibant IR capsule 20 mg
gtwjxyrnqi(mvfnntcpdq) = vuulrwvtji cnutocujdm (xbcvwwvkns, 0.4 - 0.4)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free